bisbenzimidazole has been researched along with Congenital Myotonic Dystrophy in 1 studies
Bisbenzimidazole: A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pushechnikov, A | 1 |
| Lee, MM | 1 |
| Childs-Disney, JL | 1 |
| Sobczak, K | 1 |
| French, JM | 1 |
| Thornton, CA | 1 |
| Disney, MD | 1 |
1 other study available for bisbenzimidazole and Congenital Myotonic Dystrophy
| Article | Year |
|---|---|
Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3.
Topics: Animals; Base Sequence; Bisbenzimidazole; Cell Line; Drug Design; Humans; Inhibitory Concentration 5 | 2009 |